Document is current
Any future updates will be listed below
-
Authors
Cao, Wei https://orcid.org/0000-0002-2851-4359
Lee, Hayan https://orcid.org/0000-0003-0571-3192
Wu, Wei https://orcid.org/0000-0002-6556-067X
Zaman, Aubhishek
McCorkle, Sean
Yan, Ming
Chen, Justin
Xing, Qinghe
Sinnott-Armstrong, Nasa https://orcid.org/0000-0003-4490-0601
Xu, Hongen
Sailani, M. Reza
Tang, Wenxue
Cui, Yuanbo
liu, Jia
Guan, Hongyan
Lv, Pengju
Sun, Xiaoyan
Sun, Lei
Han, Pengli
Lou, Yanan
Chang, Jing
Wang, Jinwu
Gao, Yuchi
Guo, Jiancheng
Schenk, Gundolf https://orcid.org/0000-0003-1240-9949
Shain, Alan Hunter
Biddle, Fred G.
Collisson, Eric
Snyder, Michael https://orcid.org/0000-0003-0784-7987
Bivona, Trever G. https://orcid.org/0000-0001-5734-4128
- License Information
-
More Information
Article History
Received: 20 December 2019
Accepted: 17 June 2020
First Online: 22 July 2020
Competing interests
: E.C. is consultant at Takeda, Merck, Loxo, and Pear Diagnostics, reports receiving commercial research grants from AstraZeneca, Ferro Therapeutics, Senti Biosciences, Merck KgA and Bayerand stock ownership of Tatara Therapeutics, Clara Health, BloodQ Guardant Health, Illumina, Pacific Biosciences and Exact Biosciences. T.G.B. is an advisor to Revolution Medicine, Novartis, Astrazeneca, Takeda, Springworks, Jazz, and Array Biopharma, and receives research funding from Revolution Medicine and Novartis. M.S. is Cofounder and scientific advisory board member of Personalis, SensOmics, Mirvie, Qbio, January, Filtricine, and Genome Heart. He serves on the scientific advisory board of these companies and Genapsys and Jupiter. Other authors declare no competing interests.
